Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Shares Outstanding (Weighted Average) (2016 - 2025)

Regenxbio (RGNX) has 12 years of Shares Outstanding (Weighted Average) data on record, last reported at $51.6 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 4.17% year-over-year to $51.6 million; the TTM value through Dec 2025 reached $51.6 million, up 4.17%, while the annual FY2025 figure was $51.6 million, 4.17% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $51.6 million in Q4 2025 per RGNX's latest filing, roughly flat from $51.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $51.6 million in Q4 2025 and bottomed at $41819.0 in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $33.1 million, with a median of $43.6 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): tumbled 99.89% in 2021, then skyrocketed 101080.61% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $42.4 million in 2021, then rose by 1.68% to $43.2 million in 2022, then grew by 1.35% to $43.7 million in 2023, then increased by 13.2% to $49.5 million in 2024, then rose by 4.17% to $51.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $51.6 million in Q4 2025, $51.5 million in Q3 2025, and $51.4 million in Q2 2025.